Bausch + Lomb Corporation BLCO.TO
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Ask Irving AI About BLCO.TO
Get to know the stock you’re researching through a simple conversation. Ask Irving about its Weiss rating, financial health, dividends, and potential risks — right from the stock page.
Get answers about this stock. Instantly.
Ask about the company’s financial health and its Weiss Safety, Reward, and Risk Ratings, with answers grounded in Weiss Ratings data.
Understand the numbers behind the rating.
Explore profits, cash flow, valuation, and dividends. Ask follow-up questions without leaving the stock page.
Put the stock’s strengths and risks in context.
Look beyond a single number. Explore rating changes and company trends to better understand the stock’s outlook.
Company Overview
Bausch + Lomb Corporation is a global eye health company focused on vision care, pharmaceuticals, surgical products, and consumer eye health products. The company operates in the ophthalmic and optometric healthcare industries and develops, manufactures, and markets products used for contact lens wear, cataract surgery, retinal disease treatment, dry eye management, glaucoma care, and over-the-counter eye care. Its primary revenue drivers include contact lenses, lens care solutions, ophthalmic pharmaceuticals, and surgical equipment and implants used by eye care professionals and hospitals.
The company serves ophthalmologists, optometrists, optical retailers, hospitals, ambulatory surgery centers, and consumers across developed and emerging markets. Bausch + Lomb maintains a longstanding brand presence in eye health, supported by a broad product portfolio, global distribution capabilities, and relationships with eye care professionals. The business traces its origins to 1853 in Rochester, New York, where it was founded by John Jacob Bausch and Henry Lomb. Over time, the company evolved from an optical goods manufacturer into a diversified global eye health business through internal development and acquisitions. Following periods under different ownership structures, Bausch + Lomb returned to the public markets in 2022 through an initial public offering while remaining associated with Bausch Health Companies Inc.
Business Operations
Bausch + Lomb organizes operations across major segments including Vision Care, Pharmaceuticals, and Surgical. The Vision Care business includes contact lenses, lens care products, and eye vitamins, with brands spanning daily disposable and reusable lens categories. The Pharmaceuticals segment focuses on prescription ophthalmic products for conditions such as dry eye, glaucoma, ocular inflammation, and retinal disorders. The Surgical segment supplies equipment, intraocular lenses, consumables, and devices used in cataract and vitreoretinal procedures. Revenue is generated through direct sales, distributor relationships, retail channels, and healthcare provider networks globally.
The company operates manufacturing, research, and commercial facilities across North America, Europe, Asia-Pacific, and Latin America. Bausch + Lomb controls proprietary technologies related to contact lens materials, ophthalmic drug formulations, and surgical visualization and delivery systems. Major subsidiaries and operating entities include Bausch + Lomb Incorporated and various regional commercial organizations. The company also maintains partnerships with healthcare providers, research institutions, and distribution networks to support market expansion and product development.
Strategic Position & Investments
Bausch + Lomb’s strategic direction centers on expanding its global eye health platform through innovation, portfolio diversification, and targeted acquisitions. Growth initiatives have included investments in premium contact lenses, dry eye therapies, surgical technologies, and digital capabilities supporting eye care professionals. The company has also focused on expanding penetration in emerging markets and increasing recurring revenue from consumable products within its vision care and surgical businesses.
Recent strategic activity has included acquisitions and licensing arrangements designed to strengthen ophthalmic pharmaceutical and surgical offerings. Notable acquired or integrated businesses historically associated with the company include Synergetics USA, Alden Optical, and various ophthalmic product portfolios integrated over time through predecessor ownership structures. Bausch + Lomb continues to invest in product development tied to myopia management, preservative-free eye care products, advanced intraocular lens technologies, and retinal treatment platforms. Public disclosures and investor materials indicate continued emphasis on research and development in eye health technologies and minimally invasive ophthalmic procedures.
Geographic Footprint
Bausch + Lomb operates globally with commercial activities in more than 100 countries. The company’s corporate headquarters are located in Vaughan, Ontario, Canada, while maintaining significant operational and commercial functions in the United States and internationally. Key regions include North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. Its global footprint includes manufacturing facilities, distribution centers, and research operations supporting regional demand and regulatory requirements.
The company maintains a strong market presence across both developed and emerging economies through direct operations and third-party distributors. International operations contribute a substantial portion of total revenue, reflecting broad exposure to global vision care and ophthalmic markets. Bausch + Lomb’s international influence is supported by long-established brand recognition, extensive eye care professional relationships, and localized commercial strategies tailored to regional healthcare systems and consumer demand patterns.
Leadership & Governance
Bausch + Lomb operates under a corporate governance framework overseen by its board of directors and executive leadership team. The company’s leadership strategy has emphasized long-term expansion in eye health, operational efficiency, product innovation, and global commercial growth. Since becoming a standalone publicly traded company, management has focused on strengthening market share in vision care and ophthalmic pharmaceuticals while maintaining investment in research and development.
Key executives include:
- Brent Saunders – Executive Chair and Chief Executive Officer
- Sam Eldessouky – Chief Financial Officer
- Yehia Hashad, MD – Executive Vice President, Research & Development and Chief Medical Officer
- Luc Bonnefoy – President, Global Pharmaceuticals
- Pierre Monclin – President, Global Vision Care
- Anthony Wallace – President, Global Surgical
Leadership communications and public filings indicate a strategic focus on disciplined capital allocation, expansion of the eye health product portfolio, and long-term growth through innovation and international market development.